Anastrozole, a non-steroidal aromatase inhibitor, is a cornerstone in treating hormone receptor-positive breast cancer in postmenopausal women. By suppressing estrogen production, it slows tumor growth and improves patient outcomes 11. The global market for Anastrozole tablets is projected to surpass $347.7 million by 2027, driven by rising breast cancer prevalence and strategic collaborations among pharmaceutical giants. Key Global Buyers of Anastrozole API and Tablets 1. Leading Pharmaceutical Manufacturers The following companies dominate Anastrozole production and distribution, offering both branded and generic formulations: 2. Regional Buyers and Distributors Market Trends Driving Anastrozole Procurement How to Source Anastrozole: A Buyer’s Checklist Challenges and Considerations TECNOFARMA S A KAUSTUBHA SCIENTIFIC RESEARCH LABORATORY PRIVATE L CHROMACHEMIE…